Mercer Global Advisors’s Castle Biosciences CSTL Stock Holding History

Mercer Global Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123K	Buy	+5,137	New	+$114K	﹤0.01%	3681

Other funds holding CSTL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SPPAM

Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Mercer Global Advisors's CSTL Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Castle Biosciences (CSTL) in Q2 2026: 5,137 shares worth $123K. The stake represents ﹤0.01% of the portfolio and ranks #3681 among its holdings.

167 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

Mercer Global Advisors held 5,137 shares of Castle Biosciences worth $123K as of Q2 2026.
Castle Biosciences was a new Mercer Global Advisors position in Q2 2026.
Castle Biosciences made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #3681 holding.
167 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.